VEGF-C promotes the development of esophageal cancer via regulating CNTN-1 expression

Cytokine

Volumn 55, Issue 1, 2011, Pages 8-17

  Liu, Pengfei ^a   Zhou, Jundong ^b,c   Zhu, Hong ^d   Xie, Ling ^c,d   Wang, Fangjun ^a   Liu, Bingtuan ^a   Shen, Weidong ^a   Ye, Wu ^a   Xiang, Bin ^a   Zhu, Xiaozhong ^e   Shi, Ruihua ^d   Zhang, Shuyu ^b,f  

^a JIANGYIN PEOPLE S HOSPITAL   (China)

^b MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^c SUZHOU MUNICIPAL HOSPITAL   (China)

^d THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^e AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY   (China)

^f SOOCHOW UNIVERSITY   (China)

Author keywords

C EBP; CNTN 1; Esophageal squamous cell carcinoma (ESCC); RNA interference (RNAi); Vascular endothelial growth factor C (VEGF C)

Indexed keywords

CNTN 1 PROTEIN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; MESSENGER RNA; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL ACTIVITY; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; EXPRESSION VECTOR; FEMALE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; METASTASIS; MICROVASCULATURE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; RNA TRANSLATION; TUMOR VASCULARIZATION; TUMOR VOLUME;

AGED; ANIMALS; CCAAT-ENHANCER-BINDING PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CONTACTIN 1; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HUMANS; MALE; MICE; MICROVESSELS; MIDDLE AGED; PRECANCEROUS CONDITIONS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 79956345262     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.03.008     Document Type: Article

References (41)

1. Enzinger P.C., Mayer R.J. Esophageal cancer. N Engl J Med 2003, 349:2241-2252.
2. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10-30.
3. Aurello P., D'Angelo F., Nigri G., Bellagamba R., Cicchini C., Ruzzetti R., et al. Comparison between site N-category and number N-category for nodal staging in carcinoma of the gastroesophageal junction: our experience and literature review. Am Surg 2006, 72:118-123.
4. Stacker S.A., Baldwin M.E., Achen M.G. The role of tumor lymphangiogenesis in metastatic spread. FASEB J 2002, 16:922-934.
5. Da M.X., Wu Z. Tian HW: tumor lymphangiogenesis and lymphangiogenic growth factors. Arch Med Res 2008, 39:365-372.
6. Lerut T., Coosemans W., Decker G., De Leyn P., Moons J., Nafteux P., et al. Surgical techniques. J Surg Oncol 2005, 92:218-229.
7. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004, 25:581-611.
8. Hoeben A., Landuyt B., Highley M.S., Wildiers H., Van Oosterom A.T., De Bruijn E.A. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004, 56:549-580.
9. Jain R.K. Molecular regulation of vessel maturation. Nat Med 2003, 9:685-693.
10. Joukov V., Pajusola K., Kaipainen A., Chilov D., Lahtinen I., Kukk E., et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996, 15:1751.
11. Kukk E., Lymboussaki A., Taira S., Kaipainen A., Jeltsch M., Joukov V., et al. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 1996, 122:3829-3837.
12. Alitalo K., Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 2002, 1:219-227.
13. Liu X.E., Sun X.D., Wu J.M. Expression and significance of VEGF-C and FLT-4 in gastric cancer. World J Gastroenterol 2004, 10:352-355.
14. Kitadai Y., Amioka T., Haruma K., Tanaka S., Yoshihara M., Sumii K., et al. Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas. Int J Cancer 2001, 93:662-666.
15. Furudoi A., Tanaka S., Haruma K., Kitadai Y., Yoshihara M., Chayama K., et al. Clinical significance of vascular endothelial growth factor C expression and angiogenesis at the deepest invasive site of advanced colorectal carcinoma. Oncology 2002, 62:157-166.
16. Li Q., Dong X., Gu W., Qiu X., Wang E. Clinical significance of co-expression of VEGF-C and VEGFR-3 in non-small cell lung cancer. Chin Med J (Engl) 2003, 116:727-730.
17. Witte D., Thomas A., Ali N., Carlson N., Younes M. Expression of the vascular endothelial growth factor receptor-3 (VEGFR-3) and its ligand VEGF-C in human colorectal adenocarcinoma. Anticancer Res 2002, 22:1463-1466.
18. Neuchrist C., Erovic B.M., Handisurya A., Fischer M.B., Steiner G.E., Hollemann D., et al. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck. Head Neck 2003, 25:464-474.
19. Kaushal V., Mukunyadzi P., Dennis R.A., Siegel E.R., Johnson D.E., Kohli M. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease. Clin Cancer Res 2005, 11:584-593.
20. Kodama M., Kitadai Y., Tanaka M., Kuwai T., Tanaka S., Oue N., et al. Vascular endothelial growth factor C stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms. Clin Cancer Res 2008, 14:7205-7214.
21. Dias S., Choy M., Alitalo K., Rafii S. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood 2002, 99:2179-2184.
22. Sun P., Gao J., Liu Y.L., Wei L.W., Wu L.P., Liu Z.Y. RNA interference (RNAi)-mediated vascular endothelial growth factor-C (VEGF-C) reduction interferes with lymphangiogenesis and enhances epirubicin sensitivity of breast cancer cells. Mol Cell Biochem 2008, 308:161-168.
23. Krzystek-Korpacka M., Matusiewicz M., Diakowska D., Grabowski K., Blachut K., Banas T.U. P-regulation of VEGF-C secreted by cancer cells and not VEGF-A correlates with clinical evaluation of lymph node metastasis in esophageal squamous cell carcinoma (ESCC). Cancer Lett 2007, 249:171-177.
24. Su J.L., Yang P.C., Shih J.Y., Yang C.Y., Wei L.H., Hsieh C.Y., et al. The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer cell 2006, 9:209-223.
25. World Health Organization classification of tumours: pathology and genetics of tumors of the digestive system 2000, IARC Press, Lyon, France. S.R. Hamilton, L.A. Aaltonen (Eds.).
26. Su J.L., Yang C.Y., Shih J.Y., Wei L.H., Hsieh C.Y., Jeng Y.M., et al. Knockdown of contactin-1 expression suppresses invasion and metastasis of lung adenocarcinoma. Cancer Res 2006, 66:2553-2561.
27. Jussila L., Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol Rev 2002, 82:673-700.
28. Su J.L., Yen C.J., Chen P.S., Chuang S.E., Hong C.C., Kuo I.H., et al. The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer 2007, 96:541-545.
29. Tanaka T., Ishiguro H., Kuwabara Y., Kimura M., Mitsui A., Katada T., et al. Vascular endothelial growth factor C (VEGF-C) in esophageal cancer correlates with lymph node metastasis and poor patient prognosis. J Exp Clin Cancer Res 2010, 29:83.
30. Ding M.X., Lin X.Q., Fu X.Y., Zhang N., Li J.C. Expression of vascular endothelial growth factor-C and angiogenesis in esophageal squamous cell carcinoma. World J Gastroenterol 2006, 12:4582-4585.
31. Kim H., Dumont D.J. Molecular mechanisms in lymphangiogenesis. Model systems and implications in human disease. Clin Genet 2003, 64:282-292.
32. Reid R.A., Bronson D.D., Young K.M., Hemperly J.J. Identification and characterization of the human cell adhesion molecule contactin. Brain Res Mol Brain Res 1994, 21:1-8.
33. Revest J.M., Faivre-Sarrailh C., Maeda N., Noda M., Schachner M., Rougon G. The interaction between F3 immunoglobulin domains and protein tyrosine phosphatases zeta/beta triggers bidirectional signalling between neurons and glial cells. Eur J Neurosci 1999, 11:1134-1147.
34. Sahai E., Marshall C.J. RHO-GTPase and cancer. Nat Rev Cancer 2002, 2:133-142.
35. Itoh K., Yoshioka K., Akedo H., Uehata M., Ishizaki T., Narumiya S. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med 1999, 5:221-225.
36. Hong Y.K., Lange-Asschenfeldt B., Velasco P., Hirakawa S., Kunstfeld R., Brown L.F., et al. VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins. FASEB J 2004, 18:1111-1113.
37. Goldman J., Rutkowski J.M., Shields J.D., Pasquier M.C., Cui Y., Schmokel H.G., et al. Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in adult lymphangiogenesis. FASEB J 2007, 21:1003-1012.
38. Roberts N., Kloos B., Cassella M., Podgrabinska S., Persaud K., Wu Y., et al. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res 2006, 66:2650-2657.
39. Vermeulen P.B., Gasparini G., Fox S.B., Toi M., Martin L., McCulloch P., et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996, 32A:2474-2484.
40. Fanelli M., Locopo N., Gattuso D., Gasparini G. Assessment of tumor vascularization: immunohistochemical and non-invasive methods. Int J Biol Markers 1999, 14:218-231.
41. Haggstrom S., Bergh A., Damber J.E. Vascular endothelial growth factor content in metastasizing and nonmetastasizing Dunning prostatic adenocarcinoma. Prostate 2000, 45:42-50.